FDA gains power to block Chinese drug imports, risking shortages for patients
S. 4327 — Securing America’s Drug Supply from Communist China Act · Filed by Tom Cotton (R-AR) · 1 cosponsor · Introduced Apr 16, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the FDA to review all new drug applications from Chinese entities (or entities licensing Chinese-owned drugs) submitted after enactment, and retroactively review applications submitted since January 1, 2016, to determine if the sponsor is affiliated with the Chinese government, Communist Party, or military. If such affiliation is found, the FDA must deny approval of new applications and block imports of already-approved drugs, unless the company divests to a non-Chinese entity within 180 days or the Secretary waives the ban due to drug shortage. The bill defines "PRC-, CCP-, or PLA-affiliated" broadly to include any entity receiving government support, including those with board members who are Chinese officials.
Why we flagged it
The bill's operative mechanism is a security-based regulatory review and import ban targeting Chinese-affiliated pharmaceutical entities. While framed as supply-chain security, it functions as a categorical exclusion of a major foreign supplier from the U.S. drug market, with significant collateral impact on patient access.
What the text implies
- Retroactive review of drugs approved since 2016 may force sudden market withdrawal of medications patients currently depend on, creating acute shortage risk even with the waiver mechanism—the bill does not require advance notice or transition periods.
- The definition of 'PRC-, CCP-, or PLA-affiliated' is extremely broad (any entity receiving 'support directly or indirectly' from the Chinese government) and may capture joint ventures, licensing partners, and supply-chain participants not directly controlled by Beijing, creating uncertainty for manufacturers.
The full analysis lists 5 implications of this text.
Who stands to gain
U.S. pharmaceutical manufacturers (reduced competition from Chinese-affiliated entities); Domestic generic drug manufacturers (market consolidation if Chinese competitors are excluded); Contract manufacturers and suppliers able to replace Chinese production